TP53 and hepatocellular carcinoma: Studies have shown that TP53 mutations in HCC patients are significantly associated with elevated serum alpha fetoprotein (AFP) levels (>300 ng/mL), larger tumor size (>5 cm), higher tumor grade (III/IV), and an increased risk of mortality (Woo et al., 2010a).